News

Rgenta Therapeutics, a biotechnology company specializing in developing oral small molecules that target RNA and RNA regulation for oncology and neurological disorders, has achieved a significant milestone

Read more...

SciRhom GmbH has successfully concluded a EUR 63 million Series A financing round, co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners

Read more...

Alteogen Inc. has announced that the Ministry of Food and Drug Safety of Korea has granted approval for its New Drug Application for Tergase® (recombinant hyaluronidase). Developed using Alteogen's proprietary Hybrozyme™ Technology

Read more...

Mirum Pharmaceuticals, Inc. has announced that the European Commission granted Marketing Authorization for LIVMARLI® oral solution, intended for treating progressive familial intrahepatic

Read more...

BIOSENIC, a clinical-stage company specializing in severe autoimmune and inflammatory diseases and cell therapy, along with its subsidiary Medsenic SAS, has filed a continuation patent application US 18/763,376 with the United States

Read more...

Roche announced today that the US Food and Drug Administration has approved the Vabysmo® 6.0 mg single-dose prefilled syringe for treating neovascular age-related macular degeneration, diabetic macular edema

Read more...

Beacon Therapeutics, a prominent player in ophthalmic gene therapy focused on restoring vision in patients with severe retinal diseases, has successfully raised $170 million in Series B funding.

Read more...

Gyre Therapeutics, a biotechnology firm focusing on chronic organ diseases, announced today that the National Medical Products Administration of China has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets.

Read more...

Senti Biosciences, Inc. announced today that it has received an $8 million grant from the California Institute for Regenerative Medicine to advance its Phase 1 clinical trial of SENTI-202. This innovative therapy,

Read more...

Sandoz has received FDA approval for Pyzchiva®, a biosimilar developed by Samsung Bioepis Co., Ltd. The approval includes formulations for subcutaneous injection and intravenous infusion

Read more...